MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2024 International Congress

    Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias

    H. Salhi, D. Maltête, S. Thobois, G. Fenelon, F. Ory, L. Defevre, G. Mangone, G. Defer, AR. Marques, S. Frismand, S. Drapier, JP. Azulay, C. Geny, G. Dupont, A. Doe-de-Maindreville, C. Barberot, D. Devos, JC. Corvol, O. Rascol, E. Audureau, P. Remy (Creteil, France)

    Objective: To investigate the efficacy of buspirone on levodopa induced dyskinesias (LID) in Parkinson disease (PD) patients Background: LID could be partially mediated by the…
  • 2024 International Congress

    Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor

    N. Shanks, S. Markova, R. Mukkavilli, L. Tan, M. Lee, E. Brigham (Palo Alto, USA)

    Objective: Present the pharmacokinetic/pharmacodynamic (PK/PD) relationship and contribution to anti-tremor efficacy for suvecaltamide and its active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a harmaline-induced rat model of…
  • 2024 International Congress

    The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)

    J. Cedarbaum, B. Koo, L. Zhang, K. Mead, S. Patel, V. Reddy, D. Hafler (New Haven, USA)

    Objective: To explore the potential for an immunologically based intervention to slow evolution of symptoms in persons with prodromal or Stage 2b (Simuni et al.…
  • 2024 International Congress

    Treatment Patterns in Essential Tremor: Real-World Evidence from Germany

    JS. Becktepe, S. Müller, T. Wilke, E. Zhuleku, K. Appiah, K. Mcdonald, N. Dzimitrowicz, J. Marshall, J. Sabater, LM. Barbato, TA. Saifee (Kiel, Germany)

    Objective: To investigate the treatment patterns (TP), healthcare resource utilization (HCRU), and costs of essential tremor (ET) in a real-world setting in Germany using insurance…
  • 2024 International Congress

    Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat

    W. Kang, Y. Kulkarni, I. Frouni, C. Kwan, D. Bédard, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…
  • 2024 International Congress

    Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate

    W. Kang, I. Frouni, S. Nuara, C. Kwan, J. Gourdon, D. Bédard, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…
  • 2024 International Congress

    Characterisation of the pharmacokinetic profile of amantadine in the common marmoset

    D. Bédard, F. Gaudette, S. Nuara, F. Beaudry, P. Huot (Montreal, Canada)

    Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…
  • 2023 International Congress

    On-demand therapy (ODT) in Parkinson’s disease: a survey of advanced practice providers

    K. Papesh, A. Merriam, C. Zebendon (Phoenix, USA)

    Objective: A survey of neurology Advanced Practice Providers (APPs) provides insights into their perspectives on managing and treating patients with Parkinson’s disease (PD) in the…
  • 2023 International Congress

    Placebo response in Parkinson’s disease (PD) is predicted by expression levels of a specific brain network

    J. Barbero, C. Tang, A. Vo, Y. Ma, S. Peng, B. Brakedal, C. Dölle, N. Brekke, C. Tzoulis, D. Eidelberg (Manhasset, USA)

    Objective: To determine whether baseline expression levels for the previously validated sham surgery-related metabolic pattern (SSRP) can be used to predict the magnitude of the…
  • 2023 International Congress

    Exercise and levodopa metabolism in Parkinson disease

    M. Figura, J. Giebułtowicz, A. Mrozowicz, S. Szlufik, D. Koziorowski (Warsaw, Poland)

    Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 36
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley